A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Soria, J Gan, H Blagden, S Plummer, R Arkenau, H Ranson, Malcolm R Evans, T Zalcman, G Bahleda, R Hollebecque, A
Soria, J
Gan, H
Blagden, S
Plummer, R
Arkenau, H
Ranson, Malcolm R
Evans, T
Zalcman, G
Bahleda, R
Hollebecque, A
Citations
Altmetric:
Abstract
Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancer patients.
Description
Date
2016-10-11
Publisher
Collections
Keywords
Type
Article
Citation
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. 2016 Ann Oncol